Effect of Hormonal Contraception on Lower Urinary Tract Symptoms& Sexual Function

Effect of hormonal contraception on lower urinary tract symptoms& sexual function

Study Overview

• Status: Unknown
• Conditions: Contraception

Detailed Description

It is generally accepted that female sex hormones influence the morphology and physiology of vaginal tissues. Peripheral estrogen affects urogenital connective tissue composition and structure, vaginal blood flow, and thickness of vaginal epithelium. Estrogen and progestagen receptors are also abundantly present in the lower urinary tract, which has the same embryonic origin as the vagina. decline in circulating estrogen levels may result in atrophy of vaginal, urethral and bladder trigonal epithelium, as well as initiate metabolic changes in the subepithelial supportive tissues. This process forms the biological rationale for the common clinical practice of prescribing hormone treatment to menopausal women with lower urinary and genital tract symptoms.

Contrary to widespread belief, the Womens Health Initiative (WHI) randomised trial showed that menopausal hormone therapy with conjugated estrogen alone, or in combination with progestagen, increased the risk of de novo or aggravated urinary incontinence after one year of treatment. In premenopausal women, oral contraception is the most common source of hormone intake but very few studies have endeavored to determine the effects of oral contraception on premenopausal urinary incontinence. The aim of this nationwide cohort study was to assess the influence of contraceptives on the risk for lower urinary tract dysfunction in young female.at is time-related with the beginning of hormonal contraception, health care providers should give information about other methods and try to switch them to a method less associated with sexual dysfunction. However, there are contradictory results between the different studies regarding the association between sexual dysfunction and hormonal contraceptives, so it could be firmly said that additional research is needed.

Meanwhile, it could be said that hormonal contraception has been associated with different alterations in sexual functioning.

To conclude, a multidisciplinary approach to the management of female sexual dysfunction is mandatory, and health care providers should give lifestyle counselling apart from proposing different treatment options. An adequate relationship with the patient, as well as the routine monitoring of possible sexual dysfunction, are essential in addressing these difficulties. Undoubtedly, the best contraceptive is one that fulfills the women's needs with acceptable side effects and agreed with the prescribed

• Study Type: Observational
• Enrollment (Anticipated): 177

Contacts and Locations

• Study Contact: Name: randa habeeb yacoup; Phone Number: +201278014811; Email: randahabeb25@yahoo.com

Study Locations

• Egypt
  • Assiut, Egypt
    • Women"S Health Hospital
    • Contact: ahmed makhlof; Phone Number: +201001795011

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

all women attending family planning clinic taking hormonal contraception

Description

Inclusion Criteria:

1. Women taking hormonal contraception e.g cocs .pops.implanon&.injectable contraception
2. Women has good regular marital life

Exclusion Criteria:

1. female has organic urinary dysfunction
2. female has mental& psycological dysfunction
3. chronic disease DM.hypertension. chronic renal disease
4. prolapse
5. previous perineal &vaginal correlation surgery
6. women taking any treatment for urinary tract infection &sexual dysfunction

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Arabic female sexual function index	valid questionnaire that can be used in the Egyptian population. The questionnaire is relatively easy to be understood by lay women and does not contain unacceptably sexually explicit questions, which may pose difficulties for self-rating. ArFSf I is valid and reliable,and it is as good as the original FSFI in assessing female sexual function &good psychometric tool for sexual dysfunction . Research in the area of female sexuality is not easy and relatively challenging in the Arab world	baseline
Bristol female lower urinary tract symptoms questionnaire	it was designed to asses lower urinary tract symptoms in women & quality of sexual life . it will be translated into arabic language	baseline

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Chair: muhmoud zakhera, Assiut University; Study Chair: mostafa bahlool, Assiut University

Publications and helpful links

General Publications

• Batra SC, Iosif CS. Progesterone receptors in the female lower urinary tract. J Urol. 1987 Nov;138(5):1301-4. doi: 10.1016/s0022-5347(17)43588-9.
• Champaneria R, D'Andrea RM, Latthe PM. Hormonal contraception and pelvic floor function: a systematic review. Int Urogynecol J. 2016 May;27(5):709-22. doi: 10.1007/s00192-015-2833-3. Epub 2015 Sep 25.
• de Castro Coelho F, Barros C. The Potential of Hormonal Contraception to Influence Female Sexuality. Int J Reprod Med. 2019 Mar 3;2019:9701384. doi: 10.1155/2019/9701384. eCollection 2019.

Study record dates

Study Major Dates

• Study Start (Anticipated): April 15, 2020
• Primary Completion (Anticipated): September 15, 2021
• Study Completion (Anticipated): October 15, 2021

Study Registration Dates

• First Submitted: April 4, 2020
• First Submitted That Met QC Criteria: April 6, 2020
• First Posted (Actual): April 7, 2020

Study Record Updates

• Last Update Posted (Actual): April 7, 2020
• Last Update Submitted That Met QC Criteria: April 6, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urological Manifestations; Lower Urinary Tract Symptoms
• Other Study ID Numbers: hormonal contraception

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No